Fast-Track:Biomagnetic In-vivo Imaging of Ovarian Cancer

描述（由申请人提供）：开发了一种将纳米技术应用于卵巢癌早期检测、定位和潜在治疗的新方法。最近的测量，使用活的卵巢癌细胞系和卵巢癌标志物CA-125，已经表明，这种方法的灵敏度优于105个细胞在5 - 8厘米的深度从传感器。这比超声或X射线成像所需的108个细胞要敏感得多。敏感的生物磁传感器用于测量与卵巢癌细胞或癌前病变的特异性标记物缀合的超顺磁性纳米颗粒的剩磁场。测量表明，104个纳米颗粒附着在每个癌细胞上，产生高磁矩/细胞。SQUID传感器阵列用于检测和定位这些超顺磁性纳米颗粒。为了开发临床试验方案，提出了使用纳米颗粒进行实验，用几种卵巢标记物标记，注射到卵巢模型，卵巢组织和提取的人类卵巢中。在此之后，将研究含有标记物和抗癌分子的多组分纳米颗粒，用于使用磁性浓缩的癌症破坏。在随后的临床应用中，将使用这些研究中开发的程序将标记的磁性纳米颗粒注射到患者体内。

DESCRIPTION (provided by applicant): A novel method for applying nanotechnology to the early detection, localization and potential treatment of ovarian cancer has been developed. Recent measurements, using live ovarian cancer cell lines and the ovarian cancer marker CA-125, have shown that the sensitivity of this method is better than 105 cells at depths of 5 - 8 cm from the sensor. This is significantly more sensitive than the 108 cells required for ultrasound or x-ray imaging. Sensitive biomagnetic sensors are used to measure the remanence fields of superparamagnetic nanoparticles conjugated with specific markers for ovarian cancer cells or pre-cancerous lesions. Measurements indicate that 104 nanoparticles attach to each cancer cell yielding a high magnetic moment/cell. An array of SQUID sensors are used to detect and localize these superparamagnetic nanoparticles. In order to develop protocols for clinical trials, experiments are proposed using nanoparticles, labeled with several ovarian markers, injected into phantom ovaries, ovarian tissue, and extracted human ovaries. Following this, multicomponent nanoparticles, containing both marker and anti-cancer molecules will be investigated for cancer destruction using magnetic concentration. In subsequent clinical applications, labeled-magnetic nanoparticles will be injected into the patient using the procedures developed in these studies.